Floatz logo

lb54640

Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc.Phase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Hypothalamic Obesity cohort.

Asset / SponsorPhaseRating
Exenatide
University Hospital, Bordeaux
Phase 3BB
Octreotide Pamoate
Novartis
Phase 4BB
Tirzepatide
Grace Kim
Phase 4BB
Setmelanotide
Rhythm Pharmaceuticals, Inc.
Phase 3BB
EUDEMINE INJECTION
The Hospital for Sick Children
Phase 2B

View all 14 →

Same molecule, other indications

lb54640 is also rated in:

obesity due to prohormone convertase I deficiencyDormant
CCC
Indicative ·
53 / 100
View asset →
obesity due to leptin receptor gene deficiencyDormant
CCC
Indicative ·
53 / 100
View asset →
obesity due to pro-opiomelanocortin deficiencyDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →